Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

NCT07743632 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Cancer

Interventions

DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Ivonescimab

Sponsor

University of Kansas Medical Center